Kindeva Drug Delivery Celebrates Breaking Ground For New Headquarters

The construction of new facility in Woodbury, Minnesota is expected to create jobs

Kindeva Drug Delivery, a global contract development and manufacturing organization (CDMO) focused on complex drugs and combination products, has broken ground on its new global headquarters in Woodbury, MN. When complete, the 137,500 square foot site will house a state-of-the-art R&D laboratory, critical support functions, and corporate leadership. Over 250 employees and contractors are expected to transition to the new headquarters with room for further growth and expansion. Kindeva expects to open the facility in the second half of 2021.

The headquarters building will be vitally important to Kindeva’s US R&D operations, which will be based at the new site. Kindeva’s R&D capabilities are broad, spanning from formulation, product development, and clinical support. Activity is focused on complex drug delivery technologies, primarily metered dose inhalers (MDIs), transdermal patches, and Microstructured Transdermal Systems (microneedles). The new laboratory has been carefully designed to house Kindeva’s state-of-the-art lab equipment and promote collaboration among Kindeva’s scientists, reinforcing Good Manufacturing Practice (GMP), safety, and compliance standards.

Kindeva has been adding jobs over the past six months both to support its long-term growth trajectory and to facilitate its separation from 3M in May 2020. The construction of the new site will enable even further job growth in the state of Minnesota. “I am excited to call Woodbury the permanent home of our corporate headquarters,” said Aaron Mann, CEO of Kindeva Drug Delivery. “I believe that both the location and the modern, functional design of the facility will help us attract new talent. We appreciate the strong support from the City of Woodbury and the State of Minnesota.”

“We are delighted to welcome the global headquarters of Kindeva Drug Delivery to Woodbury,” said Woodbury Mayor Anne Burt. “As the first commercial development in this part of the community along I-94, the Kindeva project represents a new development pattern for the city, with a focus on light industrial, manufacturing and distribution uses. It will establish the northeast area as a first-class business park and offer a unique opportunity to diversify the city’s job and tax base.”

“I am proud of our state’s work to help Kindeva, an innovative Minnesota company with global operations, expand their business right here in Minnesota,” said Governor Tim Walz. “I congratulate Kindeva on growing their headquarters and creating 35 new jobs in Woodbury.”

“Kindeva’s expansion is a testament to Minnesota’s leadership in health innovation and technology,” said DEED Commissioner Steve Grove. “DEED is focused on growing jobs and empowering growth of Minnesota’s economy.”

Kindeva has a strong legacy of development-driven solutions in the pharmaceutical, biotech, and life sciences sectors. The company’s list of novel achievements includes the invention of the world’s first metered-dose inhaler (MDI) and the first-ever drug-inadhesive transdermal patch. Kindeva-developed and manufactured therapies treat patients battling a host of debilitating and chronic diseases, including respiratory illnesses and cardiovascular conditions.

“This is a great addition for Kindeva’s R&D team,” Mann commented. “The new lab will support ongoing customer projects, reinforce our strength in the development of novel and complex drug delivery solutions, and help us attract top recruits with STEM, pharma, and life sciences backgrounds.”

About Kindeva Drug Delivery
Headquartered in St. Paul, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry, specializing in solving complex drug delivery challenges. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery. Kindeva employs approximately 1,000 people worldwide, with locations in California, Minnesota, and the United Kingdom. For more information, visit www.kindevadd.com.